Xeris Biopharma Holdings, Inc.
LSE: 0A8E.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Shannon
- Employees
- 394
- Headquarters
- Chicago, United States
- IPO year
- 2021
- Market cap
- $1.1B
- Website
- https://www.xerispharma.com
Loading 0A8E…
Loading profile data…Frequently asked questions about 0A8E
What does Xeris Biopharma Holdings, Inc. (0A8E.L) do?
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
Where does 0A8E.L trade?
Xeris Biopharma Holdings, Inc. (0A8E.L) trades on the London Stock Exchange.
What sector is 0A8E.L in?
Xeris Biopharma Holdings, Inc. (0A8E.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Xeris Biopharma Holdings, Inc.?
John Shannon is the chief executive officer of Xeris Biopharma Holdings, Inc. (0A8E.L).
Where is Xeris Biopharma Holdings, Inc. headquartered?
Xeris Biopharma Holdings, Inc. is headquartered in United States.
Does 0A8E.L pay a dividend?
Xeris Biopharma Holdings, Inc. (0A8E.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0A8E.L go public?
Xeris Biopharma Holdings, Inc. (0A8E.L) completed its initial public offering in 2021.